Lactulose
Synthetic galactose-fructose disaccharide: osmotic laxative, ammonia-lowering therapy, and bifidogenic prebiotic
What is Lactulose?
Lactulose (Galactose-fructose disaccharide) is a prebiotic fiber used for reduces mortality and improves/prevents overt hepatic encephalopathy in cirrhosis (cochrane rr ~0.59 for death; ~0.58 for he) by trapping gut-derived ammonia as ammonium and accelerating its excretion. NutriDex grades the human evidence as Strong. Lactulose is a non-absorbable synthetic disaccharide (galactose linked to fructose) that passes undigested to the colon, where bacteria ferment it into short-chain fatty acids that acidify the lumen, trap ammonia as ammonium, and exert an osmotic laxative effect. Its strongest evidence is in hepatic encephalopathy: a 2016 Cochrane review of randomized trials found non-absorbable disaccharides reduce mortality (RR ~0.59) and improve/prevent overt and minimal encephalopathy, making it first-line therapy. For chronic constipation it reliably increases stool frequency, though head-to-head trials show polyethylene glycol (PEG/macrogol) outperforms it on most outcomes. At low (sub-laxative) doses lactulose acts as a bifidogenic prebiotic and modestly enhances colonic calcium absorption, but these microbiome and mineral-absorption uses rest on smaller, shorter trials and are less robust than its gastroenterology indications.
Purported Benefits
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Reduces mortality in hepatic encephalopathyCochrane (24 RCTs): non-absorbable disaccharides reduce death (RR 0.59). First-line, robust. | Strong | ↑ benefit · large | 1 |
| Improves/reverses overt and minimal hepatic encephalopathyCochrane, meta-analysis, and multicenter RCT (64% vs 23% MHE reversal) all consistent. | Strong | ↑ benefit · large | 3 |
| Increases stool frequency in chronic constipationNetwork meta-analysis: +3.4 weekly BMs vs placebo; but PEG outperforms it head-to-head. | Strong | ↑ benefit · moderate | 2 |
| Bifidogenic prebiotic effect (microbiome/SCFA)Low-dose bifidogenic/SCFA effect rests on smaller, shorter trials and review-level data. | Preliminary | ↑ benefit · moderate | 1 |
| Enhances colonic calcium absorptionSingle small crossover trial (n=12) showed dose-dependent rise (27.7%→32.2%); limited evidence. | Preliminary | ↑ benefit · small | 1 |